Abstract: The present invention provides a composition based on cannabidiol (CBD) and chitosan for use in reducing blood cholesterol, blood LDL and blood triglycerides levels.

Abstract: Embodiments concern an intraocular implantable device operable comprising a disk-shaped body having a symmetry axis and which further comprises a light-transmissive portion and an opaque portion wherein the light-transmissive portion is decentered with respect to the symmetry axis.

Abstract: Embodiments pertain to ureteral stents for treatment of partial or full ureteral occlusion by bridging one or more ureteral occlusions, where each stent includes a tubular portion, a first spout portion and a second spout portion. The stent may have one or more tapered edges by having the smallest diameter of the first and/or the second spout portion smaller than the largest diameter of the tubular portion, and/or be of an overall length allowing the ureteral stent to be completely located within a patient's ureter once deployed therein.

Abstract: A method of distinguishing sleep period states that a person experiences during a sleep period, the method comprising: using a non-contact microphone to acquire a sleep sound signal representing sounds made by a person during sleep; segmenting the sleep sound signals into epochs; generating a sleep sound feature vector for each epoch; providing a first model that gives a probability that a given sleep period state experienced by the person in a given epoch exhibits a given sleep sound feature vector; providing a second model that gives a probability that a first sleep period state associated with a first epoch transitions to a second sleep period state associated with a subsequent second epoch; and processing the feature vectors using the first and second models to determine a sleep period state of the person from a plurality of possible sleep period states for each of the epochs.

Abstract: A method of predicting an analyte level comprises receiving a time-ordered series of levels of the analyte, monitored over a time-period; feeding a trained neural network procedure with the monitored levels; and displaying, based on an output received from the procedure, a predicted level of the analyte in a future time. The procedure can comprise a plurality of layers, wherein for at least one pair of layers, a number of inter-layer connections within the pair is higher for later monitored levels than for earlier monitored levels.

Abstract: A new approach is presented to reduce encrustation of catheters by the application of nanoparticles. It is demonstrated that the negatively surface charged nanoparticles produce coating films comprised of long-range domains in which the nanoparticles are self-assembled into a mosaic-like order, showing a relatively small tendency to agglomerate.

Abstract: According to some embodiments there is provided a wearable device for breast screening, comprising: at least one breast-contacting member shaped to contact a surface of a breast, the member comprising an array of force applying units and an array of sensors configured for sensing at least one parameter in response to force applied by the force applying units; the force applying units and the sensors disposed on or within the breast-contacting member and positioned to contact a surface of the breast; a memory storing one or more patterns suitable to detect a lump underlying the surface; wherein the pattern comprises a sequence of forces that vary spatially and/or vary in time; a controller configured for: reading data from the memory to control application of force; communicating with the sensors to receive signals associated with the at least one parameter sensed in response to the application of force; and to process the received signals to detect a lump.

Abstract: The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.

Abstract: A method of determining a value for an apnea-hypopnea index (AHI) for a person, the method comprising: recording a voice track of a person; extracting features from the voice track that characterize the voice track; and processing the features to determine an AHI.

Abstract: A method of treating a malignant disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a first liquid chromatography fraction of a cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), and a therapeutically effective amount of a second liquid chromatography fraction of a cannabis extract comprising at least 75% cannabigerolic acid (CBGA), wherein the first liquid chromatography fraction comprises cannabis derived active ingredients other than the THCA, and the second liquid chromatography fraction comprises cannabis derived active ingredients other than the CBGA, thereby treating the malignant disease in the subject.

Abstract: Compositions and methods for the treatment of cutaneous T cell lymphoma (CTCL) are provided. The compositions and uses thereof comprise cannabinoids.

Abstract: A catheter for removable insertion into a body vasculature has at least one inflatable member. The catheter has at least in part an expandable body that forms an internal axially extending lumen in at least the expanded state of the body. The inflatable member is adjacent a distal axial end of the body and is configured to at least partially obstruct the lumen.

Abstract: Embodiments concern an optical eye-contact device comprising a lens body having a symmetry axis and which further comprises a light-transmissive portion and an opaque portion, wherein the light-transmissive portion is decentered with respect to the symmetry axis.

Abstract: A method for evaluating a treatment for a brain condition, including: extracting one or more microstate parameter values from at least one EEG signal that was measured after the treatment; and evaluating at least one parameter of the treatment based on the one or more microstate parameter values.

Abstract: Embodiments relate to an implantable device for detecting leakage of matter from a mammalian lumen, the device comprising a mesh structure that is attachable to a lumen of a mammalian. The mesh structure comprises a material or a material composition that is electrically conductive and which is measurably responsive in terms of its electrical conductivity when being subjected to leakage of matter from the lumen.

Abstract: The invention provides isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within said peptides. Pharmaceutical compositions comprising said peptides and antibodies are also disclosed as well as methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders.

Abstract: According to some embodiments there is provided an anastomosis device configured to reduce leakage, comprising: a first set of rings sized to be positioned at a first tissue wall; a second set of rings sized to be positioned at a second tissue wall adjacent the first tissue wall; and an element configured to draw the ring sets towards each other; wherein each set of rings comprises an inner ring, an outer ring, and a coupling for aligning the inner and outer rings with respect to each other; wherein the inner ring applies a first pressure onto the tissue wall which is sufficient to gradually form a passage between the first and second tissue walls; and the outer ring applies a second pressure onto the tissue wall, the second pressure applied radially outwardly relative to the first pressure, the second pressure sufficient to reduce leakage in a vicinity of the passage.

Abstract: Use of activated protein C (APC) for treatment and prevention of ocular diseases, disorders or conditions associated with retinal leakage and CNV such as age-related macular degeneration, optionally in combined therapy with anti-angiogenesis, anti-inflammatory, immunosuppressive, and anti PDGF agent.

Abstract: Described herein are methods for determining the prognosis of a patient diagnosed with Acute Lymphoblastic Leukemia (ALL), and particularly determining the risk of disease relapse following standard treatment. Also described are systems of treatment that are directed by a health care provider, and which include the described prognostic methods and the treatments recommended for patients determined to have a specific relapse risk.

Abstract: Described herein is the correlation between miR-451 expression and the increased benefit of a treatment modality of solid tumors that effects miR-451 modulated metabolic pathways. Such modalities include NAMPT inhibitors and/or PARP inhibitors. Also described herein are methods for treatment of solid tumors that include determining whether treatment of the tumor would benefit from inhibition of NAMPT and/or PARP and if so, treating the patient afflicted with the tumor with NAMPT and/or PARP inhibitors.